The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. The majority of current candidate vaccines aim to induce an antibody response against the spike protein. “As

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

XTalks

JANUARY 6, 2021

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody. TJ” Esparza, BS, and David L.

Antibody 105

Antibody Protein Bacteria In-Vitro 105

Drug Discovery World

MAY 25, 2023

Following the Scottish Research and Drug Development Forum meeting, DDW’s Diana Spencer provides a snapshot of drug discovery in Scotland. Introduction to the CRUK Beatson Institute The first speaker was Professor Owen Sansom, Director of the Cancer Research UK Beatson Institute, who gave two presentations.

Research 52

Research Drugs In-Vitro Insulin 52

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies. We were there to present the latest findings from our research. MT: What’s next for STORM’s research? MT: What data did you present at the conference?

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

OCTOBER 27, 2023

Organ-chips combine cell culture with microfluidics to emulate the biological forces of different organ tissues and/or disease states, allowing pharmaceutical researchers to determine a drug candidates’ efficacy and toxicity ahead of clinical trials. Could organ-chips replace other research methods? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

Roots Analysis

AUGUST 15, 2023

Overview of Cell Free Systems Cell-free systems are ­in-vitro platforms which allow occurrence of biochemical reactions in the absence of living cells. Additionally, these types of cell free systems do not contain proteases and nucleases as crude cell lysates, which further helps in improving the production of many proteins.

Protein 52

Protein In-Vitro Production Reagent 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Etienne De Braekeleer, Senior Research Scientist, AstraZeneca.

In-Vitro 52

In-Vitro Engineer Scientist Gene Therapy 52

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

MARCH 25, 2022

AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been recommended for marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg.

Antibody 52

Antibody In-Vivo Medicine Vaccination 52

Drug Discovery World

MARCH 8, 2023

Dosing has begun in a Phase I clinical study evaluating BAT8008, an antibody-drug conjugate (ADC) that targets Trop2. Key objectives of the study are to determine the maximum tolerated dose (MTD), recommended Phase II dose (RP2D), and to evaluate the pharmacokinetics and preliminary efficacy in patients with advanced solid tumours.

Trials 52

Trials In-Vivo In-Vitro Antibody 52

Delveinsight

JANUARY 12, 2021

Birinapant is a clinical-stage SMAC mimetic that degrades Inhibitors of Apoptosis Proteins (IAPs) by binding to them, ultimately leading to cell death in tumor cells. It is an IgM antibody targeting Death Receptor 5 (DR5), and IGM is hoping to test Birinapant with IGM-8444 for the treatment of solid cancers later this year.

Licensing 52

Licensing Licensing Antibody Gene Therapy 52

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June. months, 39.4%

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. Regeneron has progressed the REGN-COV2 research and development program at record speed and worked tirelessly to maximize our in-house manufacturing capacity,” said Leonard S. Schleifer, M.D.,

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

XTalks

JANUARY 27, 2021

The company used in vitro neutralization antibody studies to evaluate the activity of Moderna’s vaccine-generated antibodies in human sera against several variants of the novel coronavirus, including the B.1.1.7 The in vitro study evaluated the ability of mRNA-1273-generated antibodies to neutralize the new SARS-CoV-2 variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

XTalks

MARCH 6, 2024

Brain Awareness Week 2024 , taking place March 11 to 17 this year, is a global campaign that aims to demystify the complexities of the human brain and promote the significance of neuroscientific research. The week-long celebration is also a call to action for increased support and funding for neurological and psychological research.

FDA Approval 69

FDA Approval In-Vitro Research Marketing 69

XTalks

JUNE 30, 2023

Sartorius is a globally recognized player in the diagnostics industry, providing a variety of solutions for in vitro diagnostics kit (IVD) manufacturers. “By working with customers from the initial research stage through to the development stage and finally the production stage, Sartorius can address and remove any issues. .

In-Vitro 52

In-Vitro Manufacturing Production Antibody 52

Roots Analysis

NOVEMBER 30, 2021

Further, various researchers have demonstrated that the cell and gene therapies show different mechanism of actions; majority of the times these actions are unpredictable. Most of the facilities are providing in vitro bioassay services for cell and gene therapies. Companies Offering Bioassay Services for Cell and Gene Therapies.

Bioassay 52

Bioassay Gene Therapy Gene Development 52

The Pharma Data

SEPTEMBER 1, 2020

with whom Roche has a global distribution agreement and had also launched a Rapid Antibody Test in July. Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions. Roche also intends to file for Emergency Use Authorisation (EUA) to the U.S.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

pharmaphorum

JANUARY 17, 2023

Research into mRNA dates back to the 1970s, but with the approval of both Moderna and BioNTech/Pfizer’s vaccines, this approach has finally been validated. As it stands, mRNA vaccines and therapeutics can only provide benefits if they can reach the living cells and be processed into protein.

Vaccination 79

Vaccination Vaccine In-Vivo In-Vitro 79

The Pharma Data

MARCH 16, 2021

The test runs on widely used high-throughput systems and is for research purposes only. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

OCTOBER 13, 2022

Over the two days at ExCel, 1554 delegates attended the event. Of those delegates, 75% work in drug discovery. There were 127 exhibitors, 180 posters, 40 technology speakers, 52 scientific speakers as well as a series of eight seminars focused on automation and technology which DDW organised and moderated in the dedicated Tech Theatre. .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. In addition, to meet U.S.

Research 112

Research Vaccination Vaccine Drugs 112

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. Ronapreve is a combination of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Antibody 52

Antibody Medicine Production In-Vitro 52

Drug Discovery World

AUGUST 3, 2022

Over the years, a range of different CPPs have been developed, including natural translocating proteins through to newly-designed computer-prediction sequences 3. This is a common reaction within peptide chemistry and it has been approved by regulatory authorities for various antibody-drug conjugates 4. Nanoparticles 6.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

JULY 22, 2022

As a result, researchers are striving to continually improve immuno-oncology approaches using the patient’s own immune cells to combat tumours. To mitigate these risks, clinicians are turning to other immunomodulators, such as cell-based therapies, bispecific antibodies, and cytokine treatments.

In-Vivo 52

In-Vivo Engineer In-Vitro Medicine 52

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. The antibodies are conjugated to fluorochromes for them to be detected. The webinar also showed two examples of receptor occupancy assays conducted by Medpace for sponsors.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

The Pharma Data

AUGUST 6, 2020

Safety for the Tecentriq combination appeared to be consistent with the known safety profile of the individual medicines, and no new safety signals were identified. Roche’s Chief Medical Officer and Head of Global Product Development. This includes studies evaluating Tecentriq both alone and in combination with other medicines.

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

APRIL 23, 2021

Roche announces positive CHMP opinion for Venclyxto-based combinations in certain patients with acute myeloid leukaemia. Venclyxto combinations significantly improved complete response rates in people with newly diagnosed acute myeloid leukaemia in two key studies (VIALE-A and M14-358). The median OS was 14.7 months (95% CI: 11.9, months (95% CI: 7.4,

Medicine 40

Medicine In-Vitro Antibody Branding 40

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. AbbVie has initiated a Phase I clinical trial of the antibody, and it will conduct the initial clinical program in the U.S. before expanding it into Europe.

Antibody 52

Antibody Licensing Licensing In-Vitro 52

Camargo

NOVEMBER 29, 2021

Recombinant therapeutic proteins. Fusion proteins. Monoclonal antibodies (mAbs). Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available. Gene and cellular therapies. Interferons.

Development 180

Development Protein Production Hormones 180

Drug Discovery World

FEBRUARY 1, 2024

This paid-for advertorial by Twist Bioscience appeared in the Therapeutic Antibodies Guide – DDW Volume 25 – Issue 1, Winter 2023/2024 Improving gene synthesis speed can reduce workflow times, saving you invaluable time, says Twist Bioscience. Traditionally, therapeutic antibody discovery is labour and resource intensive.

Antibody 64

Antibody Gene Protein Manufacturing 64

The Pharma Data

APRIL 27, 2021

The advisory committee provides the FDA with independent opinions and recommendations from outside medical experts, though the recommendations are not binding. The FDA has not announced when it will make its final decision for Tecentriq in this indication. Roche’s Chief Medical Officer and Head of Global Product Development.

Medicine 40

Medicine In-Vitro Antibody Development 40

Drug Discovery World

APRIL 11, 2024

The Program Committee Chairs commented: “It has been an educational, enlightening, and inspiring week of captivating cancer science and research. Research highlights Blacksmith Medicines announced preclinical data on its oncology programme targeting flap endonuclease 1 (FEN1). And thanks to the city of San Diego for its hospitality.”

HR 52

HR Antibody In-Vitro DNA 52

XTalks

NOVEMBER 7, 2022

Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

SEPTEMBER 19, 2020

Data from the Phase III IMpassion031 study demonstrated that Tecentriq in combination with chemotherapy improved pathological complete response for patients with early triple-negative breast cancer (TNBC), when compared to placebo plus chemotherapy. Roche’s Chief Medical Officer and Head of Global Product Development. from 41.1% (95% CI: 33.6–48.9)

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

JANUARY 6, 2021

Studies Show Cyto-111 Enables Delivery of Antibodies to Previously Inaccessible Intraneuronal Targets without the need for a Viral Vector or Transfection. The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re. NEW YORK, Jan.

Medicine 52

Medicine Antibody Protein In-Vitro 52